Research prototype, not medical advice.

In the PEARL trial (1 year, low doses), rapamycin is well tolerated with modest effects on some markers.

Confidence
Debated
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Disabled macroautophagyRapamycin (and analogues: everolimus)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
Moel et al. · Aging 2025
— Verified